{"id":335895,"date":"2019-08-02T02:00:00","date_gmt":"2019-08-02T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/traitement-antihormonal-premenopausique-adjuvant\/"},"modified":"2019-08-02T02:00:00","modified_gmt":"2019-08-02T00:00:00","slug":"traitement-antihormonal-premenopausique-adjuvant","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/traitement-antihormonal-premenopausique-adjuvant\/","title":{"rendered":"Traitement antihormonal pr\u00e9m\u00e9nopausique adjuvant ?"},"content":{"rendered":"<p><strong>Les femmes pr\u00e9m\u00e9nopaus\u00e9es n\u00e9cessitant un traitement antihormonal ne doivent \u00eatre trait\u00e9es par tamoxif\u00e8ne que si le risque est faible. Dans le cas contraire, il est obligatoire d&#8217;avancer la m\u00e9nopause.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>La question a \u00e9t\u00e9 pos\u00e9e de savoir s&#8217;il fallait faire une distinction entre les pr\u00e9parations chez les femmes pr\u00e9m\u00e9nopaus\u00e9es ou si toutes les options th\u00e9rapeutiques pouvaient \u00eatre utilis\u00e9es indiff\u00e9remment. Les traitements disponibles sont le tamoxif\u00e8ne, les inhibiteurs de l&#8217;aromatase, les analogues de la GnRH et le fulvestran. La stratification des risques constitue la base de la d\u00e9cision th\u00e9rapeutique.<\/p>\n<p>En principe, toute femme atteinte d&#8217;une tumeur \u00e0 r\u00e9cepteurs hormonaux positifs doit recevoir un traitement antihormonal. Chez les femmes pr\u00e9m\u00e9nopaus\u00e9es \u00e0 faible risque, l&#8217;administration de tamoxif\u00e8ne est en principe suffisante. Toutefois, les femmes de moins de 35 ans devraient \u00eatre m\u00e9nopaus\u00e9es &#8211; m\u00eame si la biologie de la tumeur est bonne. Les r\u00e9sultats de deux \u00e9tudes indiquent que dans ce cas, une combinaison d&#8217;analogues de la GnRH et d&#8217;inhibiteurs de l&#8217;aromatase peut \u00eatre b\u00e9n\u00e9fique. Cette approche est d&#8217;autant plus valable pour les femmes \u00e0 haut risque qui ont d\u00e9j\u00e0 subi une chimioth\u00e9rapie.<\/p>\n<p>&nbsp;<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-12146\" alt=\"\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2019\/08\/kasten_oh2-3_s38.png\" style=\"height:186px; width:400px\" width=\"697\" height=\"324\"><\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"duree-du-traitement-dau-moins-cinq-ans\">Dur\u00e9e du traitement d&#8217;au moins cinq ans<\/h2>\n<p>La question relative \u00e0 la dur\u00e9e d&#8217;une telle th\u00e9rapie a \u00e9t\u00e9 pos\u00e9e comme suit : &#8220;au moins cinq ans&#8221;. Pour les femmes pr\u00e9sentant un faible risque de r\u00e9cidive, un traitement de cinq ans est g\u00e9n\u00e9ralement suffisant. En revanche, les patientes qui pr\u00e9sentent un risque tr\u00e8s \u00e9lev\u00e9 de r\u00e9cidive d\u00e8s le d\u00e9but du traitement doivent, dans la mesure du possible, \u00eatre trait\u00e9es sur une p\u00e9riode deux fois plus longue, soit dix ans. L&#8217;essentiel est qu&#8217;un traitement endocrinien soit mis en place.<\/p>\n<p><em>Source : Congr\u00e8s St. Gallen International Breast Cancer Conference 2019<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>InFo ONKOLOGIE &amp; H\u00c4MATOLOGIE 2019 ; 7(2-3) : 38 (publi\u00e9 le 21.6.19, ahead of print)<\/em><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les femmes pr\u00e9m\u00e9nopaus\u00e9es n\u00e9cessitant un traitement antihormonal ne doivent \u00eatre trait\u00e9es par tamoxif\u00e8ne que si le risque est faible. Dans le cas contraire, il est obligatoire d&#8217;avancer la m\u00e9nopause.<\/p>\n","protected":false},"author":7,"featured_media":90302,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancer du sein hormono-positif","footnotes":""},"category":[11404,11422,11389,11535,11549],"tags":[28248,28244,28253],"powerkit_post_featured":[],"class_list":["post-335895","post","type-post","status-publish","format-standard","has-post-thumbnail","category-endocrinologie-et-diabetologie","category-gynecologie","category-oncologie","category-rapports-de-congres","category-rx-fr","tag-cancer-du-sein-hormono-positif","tag-therapie-endocrinienne","tag-traitement-antihormonal-premenopausique","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-17 00:30:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":335911,"slug":"terapia-ormonale-adiuvante-in-premenopausa","post_title":"Terapia ormonale adiuvante in premenopausa?","href":"https:\/\/medizinonline.com\/it\/terapia-ormonale-adiuvante-in-premenopausa\/"},"pt_PT":{"locale":"pt_PT","id":335918,"slug":"terapia-anti-hormonal-adjuvante-pre-menopausa","post_title":"Terapia anti-hormonal adjuvante pr\u00e9-menopausa?","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-anti-hormonal-adjuvante-pre-menopausa\/"},"es_ES":{"locale":"es_ES","id":335875,"slug":"terapia-antihormonal-premenopausica-adyuvante","post_title":"\u00bfTerapia antihormonal premenop\u00e1usica adyuvante?","href":"https:\/\/medizinonline.com\/es\/terapia-antihormonal-premenopausica-adyuvante\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=335895"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335895\/revisions"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=335895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=335895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=335895"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=335895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}